Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is well-positioned with its strong global presence and upcoming product launches in the diabetes technology market, and has received positive feedback for its current products. However, there are potential risks to consider, such as competition and regulatory challenges, and it will be important for the company to continue its focus on customer needs and developing new technologies to drive recurring revenue streams. Its strong financial position and unique business model provide a solid foundation for future growth, but potential challenges in international expansion will need to be carefully managed.

Bears say

Minimed Group is facing potential challenges with the intense competition in the diabetes technology market, which may have a negative impact on its market share and profitability. Additionally, risks such as potential pricing pressure, regulatory and reimbursement changes, and shifting market dynamics also pose a threat to the company's growth and profitability. Furthermore, the company's heavy reliance on international markets for its revenue growth and the uncertainty surrounding Medicare's competitive bidding process may also negatively affect its financial performance in the future.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of Jun 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.